SCHEMBL436539

SCHEMBL436539

CN1CCN(CC(=O)N(C)c2ccc(N)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.50
LMNA P02545 3/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MELK Q14680 8/20 0.47
CHEK1 O14757 3/20 0.47
PRKAB2 O43741 3/20 0.47
NUAK1 O60285 3/20 0.47
MAPK1 P28482 3/20 0.47
PRKAG1 P54619 3/20 0.47
PRKAA2 P54646 3/20 0.47
PRKAA1 Q13131 3/20 0.47
CAMKK2 Q96RR4 3/20 0.47
PRKAG3 Q9UGI9 3/20 0.47
PRKAG2 Q9UGJ0 3/20 0.47
PRKAB1 Q9Y478 3/20 0.47
HRH3 Q9Y5N1 1/20 0.43
PDGFRB P09619 2/20 0.40
FGFR1 P11362 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4490990 0.95 DRD4 (0.46) DRD4LMNANPC1RAB9ASMN1; SMN2
SCHEMBL28073437 0.90 DRD4 (0.42) DRD4LMNANPC1RAB9ASMN1; SMN2
SCHEMBL17976084 0.89 DRD4 (0.48) DRD4LMNANPC1RAB9ASMN1; SMN2
SCHEMBL4487965 0.88 DRD4 (0.50) DRD4LMNASMN1; SMN2MELKCHEK1
SCHEMBL3158672 0.88 DRD4 (0.49) DRD4LMNAHRH3ALDH1A1GFER
SCHEMBL30921473 0.88 DRD4 (0.49) DRD4LMNAMAPK1HRH3ALDH1A1
SCHEMBL24538671 0.87 DRD4 (0.49) DRD4LMNANPC1RAB9ASMN1; SMN2
SCHEMBL4481019 0.87 LMNA (0.46) DRD4LMNAALDH1A1KDM4ETSHR
SCHEMBL8256016 0.87 LMNA (0.52) DRD4LMNANPC1RAB9ASMN1; SMN2
SCHEMBL7347657 0.87 LMNA (0.49) LMNANPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3747864-B1 A METHOD FOR PREPARING METHYL (Z)-3-[[4-[METHYL[2-(4-METHYL-1-PIPERAZINYL)ACETYL]AMINO]PHENYL]AMINO]PHENYLMETHYLENE)-OXINDOLE-6-CARBOXYLATE (INTEDANIB, NINTEDANIB) Midas Pharma GmbH (DE) 2025-01-08 EP claimed
CN-115181078-B Synthesis method of Nidamib key intermediate 安徽修一制药有限公司 2024-07-19 CN claimed
US-20240051920-A1 AN IMPROVED HIGHLY EFFICIENT PROCESS FOR THE PREPARATION OF NINTEDANIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF BDR LIFESCIENCES PRIVATE LIMITED (IN) 2024-02-15 US claimed
CN-111465594-B Synthesis of 2-indolinones known as intermediates for the preparation of Nidamibu 费米有限公司 2023-11-07 CN claimed
CN-111662223-B Indolinone derivatives and process for preparing intermediates thereof 四川科伦药物研究院有限公司 2023-07-14 CN claimed
EP-3710427-B1 SYNTHESIS OF A 2-INDOLINONE DERIVATIVE KNOWN AS INTERMEDIATE FOR PREPARING NINTEDANIB FERMION OY (FI) 2023-03-08 EP claimed
CN-111848486-B Method for preparing ethanesulfonic acid nintedanib 赤峰经方医药技术开发有限责任公司 2022-12-27 CN claimed
CN-115181078-A Synthesis method of nintedanib key intermediate 安徽修一制药有限公司 2022-10-14 CN claimed
US-11261158-B2 Synthesis of 2-indolinone derivatives FERMION OY (FI) 2022-03-01 US claimed
EP-3747864-A1 A METHOD FOR PREPARING METHYL (Z)-3-[[4-[METHYL[2-(4-METHYL-1-PIPERAZINYL)ACETYL]AMINO]PHENYL]AMINO]PHENYLMETHYLENE)-OXINDOLE-6-CARBOXYLATE (INTEDANIB, NINTEDANIB) ZENTIVA, K.S. (CZ) 2020-12-09 EP claimed
US-20200299275-A1 SYNTHESIS OF 2-INDOLINONE DERIVATIVES FERMION OY (FI) 2020-09-24 US claimed
EP-3328831-B1 A METHOD FOR PREPARING METHYL (Z)-3-[[4-[METHYL[2-(4-METHYL-1-PIPERAZINYL)ACETYL]AMINO]PHENYL]AMINO]PHENYLMETHYLENE)-OXINDOLE-6-CARBOXYLATE (INTEDANIB, NINTEDANIB) ZENTIVA KS (CZ) 2020-07-29 EP claimed
US-20180215735-A1 METHOD FOR PREPARING METHYL (Z)-3-[[4-[METHYL[2-(4-METHYL-1-PIPERAZINYL)ACETYL]AMINO]PHEHYL]AMINO]PHENYLMETHYLENE)-OXINDOLE-6-CARBOXYLATE (INTEDANIB, NINTEDANIB) ZENTIVA K.S. (CZ) 2018-08-02 US claimed
US-20170174625-A1 PREPARATION METHOD OF NINTEDANIB SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) 2017-06-22 US claimed
CN-104844499-B One kettle way prepares the synthetic method of Nintedanib 北京康立生医药技术开发有限公司 2017-03-08 CN claimed
CN-104844499-A Synthetic method for preparing Nintedanib through one-pot process BEIJING KANG LISHENG PHARMACEUTICAL TECHNOLOGY DEV CO LTD 2015-08-19 CN claimed
CN-104262232-A Method for preparing nintedanib SUZHOU MIRACPHARMA TECHNOLOGY CO LTD 2015-01-07 CN claimed
WO-2025233641-A1 NOVEL PHOTOINDUCIBLE KINASE INHIBITORS FOR TREATING PROLIFERATIVE AND VASOPROLIFERATIVE DISEASES SEMMELWEIS EGYETEM (HU) 2025-11-13 WO disclosed
CN-1319090-A Novel substuted indolimones, their preparation process and use as medicine BOEHRINGER INGELHEIM PHARMA (DE) 2001-10-24 CN disclosed
WO-2001027081-A1 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174625-A1 PREPARATION METHOD OF NINTEDANIB ACVR2B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NUDT1 DRD4 3534/4885LMNA 2031/4885NPC1 3994/4885
US-11261158-B2 Synthesis of 2-indolinone derivatives AZI2, AANAT, IDO1 DRD4 553/4885LMNA 2714/4885NPC1 3408/4885
US-20180215735-A1 METHOD FOR PREPARING METHYL (Z)-3-[[4-[METHYL[2-(4-METHYL-1-PIPERAZINYL)ACETYL]AMINO]PHEHYL]AMINO]PHENYLMETHYLENE)-OXINDOLE-6-CARBOXYLATE (INTEDANIB, NINTEDANIB) ALK, ACVR2B, ACVR1B DRD4 2836/4885LMNA 1387/4885NPC1 4314/4885
US-20200299275-A1 SYNTHESIS OF 2-INDOLINONE DERIVATIVES AZI2, AANAT, IDO1 DRD4 553/4885LMNA 2714/4885NPC1 3408/4885
US-20240051920-A1 AN IMPROVED HIGHLY EFFICIENT PROCESS FOR THE PREPARATION OF NINTEDANIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF JAK1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, INMT DRD4 2359/4885LMNA 3149/4885NPC1 1808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.